Please Wait
Applying Filters...
menu
    • menu
    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    Cohance Lifesciences, offers full range of CDMO services for small molecule APIs, intermediates, ADCs, Pellets and Formulations.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-01-12

    Virtual Booth

    An Enquiry

    LEBSA- Your strategic API source for niche molecules.

    Virtual Booth

    Contact Supplier

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    An Enquiry

    Menu

    Milvexian

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    DIGITAL CONTENT

    PharmaCompass
    $ API Ref.Price (USD/KG) : 68,504Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Bristol Myers Lines Up Many Launches For India With 'AI' Speed
    Bristol Myers Lines Up Many Launches For India With 'AI' Speed

    24 Dec 2025

    // ECONOMICTIMES

    https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/bristol-myers-lines-up-many-launches-for-india-with-ai-speed/articleshow/126147041.cms

    ECONOMICTIMES
    24 Dec 2025
    Share Share
    Bayer Unveils Positive Phase III Anticoagulant Data
    Bayer Unveils Positive Phase III Anticoagulant Data

    23 Nov 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20251123638167/en/Bayers-Asundexian-Met-Primary-Efficacy-and-Safety-Endpoints-in-Landmark-Phase-III-OCEANIC-STROKE-Study-in-Secondary-Stroke-Prevention

    BUSINESSWIRE
    23 Nov 2025
    Share Share
    Update On Phase 3 Librexia ACS Trial
    Update On Phase 3 Librexia ACS Trial

    15 Nov 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20251113242684/en/Update-on-Phase-3-Librexia-ACS-Trial

    BUSINESSWIRE
    15 Nov 2025
    Share Share
    Bristol Myers Squibb Presents Cardiovascular Portfolio Data
    Bristol Myers Squibb Presents Cardiovascular Portfolio Data

    03 Nov 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20251103978786/en/Bristol-Myers-Squibb-Showcases-New-Long-Term-and-Real-World-Data-From-Cardiovascular-Portfolio-at-the-American-Heart-Association-Scientific-Sessions-2025

    BUSINESSWIRE
    03 Nov 2025
    Share Share
    Milvexian Granted U.S. FDA Fast Track Designation in Phase 3 Librexia Program
    Milvexian Granted U.S. FDA Fast Track Designation in Phase 3 Librexia Program

    25 May 2023

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20230524005933/en

    BUSINESSWIRE
    25 May 2023
    Share Share
    Milvexian Granted U.S. FDA Fast Track Designation for All Three Indications
    Milvexian Granted U.S. FDA Fast Track Designation for All Three Indications

    25 May 2023

    // PRESS RELEASE

    https://johnsonandjohnson.gcs-web.com/static-files/4120e707-3112-4f0b-a1d2-7015893e855c

    PRESS RELEASE
    25 May 2023
    Share Share
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.